INTRODUCTION 1
Regulatory interactions between coding and non-coding RNAs in cells determine the 2 post-transcriptional availability of protein-coding mRNA transcripts (Chiang et al. 2010; Guo et 3 al. 2010; Shin et al. 2010; Garcia et al. 2011; Volinia and Croce 2013; Eichhorn et al. 2014; Guo 4 et al. 2014; Lee and Jiang 2017; Rissland et al. 2017; Wu and Bartel 2017) . MicroRNAs use 5 seed sequences (6 -8 bases long) to bind to microRNA Response Elements (MREs) located on 6 the 3' untranslated regions (3'UTR) of mRNAs. The mRNAs can have one or more distinct MRE 7 sites, thus being targets to multiple microRNAs, and likewise, microRNAs can bind to MRE sites 8 of several different target genes (Krek et al. 2005; Lim et al. 2005) . As is known, mRNAs belong 9 to diverse biological pathways, and thus alterations in target gene expression via microRNA 1 0 binding can impact several cellular processes, such as cell proliferation and apoptosis during 1 1 cancer development, progression, and migration. Thus, finding critical players among the 1 2 mRNA-microRNA interacting networks can yield identification of novel therapeutic targets and 1 3 biomarkers in cancers, especially for cancer subtypes that are least responsive to current 1 4 modalities of treatment. 1 5
Expression profiles of microRNAs and mRNAs (Illumina TruSeq libraries enriched for 1 6 poly-A RNAs) across many cancer types in The Cancer Genome Atlas (TCGA) were used to 1 7 infer active and functional microRNA-target interactions in different cancer types (Jacobsen et 1 8 al. 2013 ). Alternative polyadenylation of 3'UTRs in TCGA bladder cancer was shown to lead to 1 9 shortened 3'UTR affecting mRNA stability and attenuated protein translation (Han et al. 2018 ).
0
Studies have also shown that the presence of SNPs along 3'UTR of genes affect microRNA 2 1 binding and are associated with multiple cancer subtypes (Pelletier and Weidhaas 2010). 2 2 However, to our knowledge, no work has been done so far to extrapolate RNA-Seq data to 2 3 analyze MRE sites and obtain insights into unique interactions between mRNAs and microRNAs 2 4 at the 3'UTR regions in the tumor and normal-adjacent datasets. 2 5 expression. Studies have shown that shortening of 3'UTR is a frequent phenomenon in cancer 1 to evade oncogenes from microRNA suppression (Xue et al. 2018 ), repress tumor suppressor 2 genes (Park et al. 2018 ) and enhance metastatic burden (Andres et al. 2018) . Therefore, it is 3 important not only to know which mRNAs are differentially expressed between a tumor and 4 normal pair but also to determine which integration sites or MREs are available along the 5 3'UTRs of the tumor mRNAs. Identification of MREs that are either present/absent/highly 6 expressed/low expressed in the tumor can potentially shed light on determining the mechanistic 7 nature of tumor progression. While mRNA-microRNA integration tools exist and may be applied 8 to the tumor and normal data, none, to our knowledge, have the ability to precisely report 9 mRNA-microRNA interaction that is solely based on the availability of MREs at the 3'UTR 1 0 regions. MREs are short 6 -8 base segments and without appropriate bioinformatics methods, 1 1 screening RNA-Seq data for MRE sites can yield highly non-specific and erroneous results. This 1 2 could be a possible reason why this simple, but the highly germane concept has not been 1 3 explored to date. 1 4
In this study, we developed an innovative bioinformatics method called ReMIx that uses 1 5 RNA-Seq data to identify and quantify microRNA binding sites (commonly known as microRNA 1 6
Response Elements -MREs) at 3'UTR regions of genes. We applied this methodology to TCGA 1 7 paired tumor and normal-adjacent breast cancer cases for TN, ER+, and HER2+ subtypes. 1 8
Using two complementary statistical approaches, we identified 210 MRE sites that have a 1 9 distinct expression in TN tumor-normal adjacent pairs. Upon de-coupling, we found that the 210 2 0 MRE sites corresponded to 82 mRNAs and 122 microRNAs. By reviewing fold changes of these 2 1
MREs, gene transcripts, and microRNAs, we observed that most of the MREs followed the 2 2 same direction as their parent genes. We postulate that this is likely driven by the nature of the 2 3 sequencing library preparation kit (Illumina TruSeq). However, we also found a few MREs with 2 4 the opposite trend, potentially indicating an alternate 3'UTR mechanism for the gene. 2 5 Furthermore, we found genes and MREs with positive expression in TNBC tumors but 1 repressed microRNAs, likely indicating the effect of competing endogenous RNAs (ceRNAs) on 2 the microRNAs. Canonical pathway analysis on both mRNAs and microRNAs revealed cancer-3 related pathways specific to breast cancer. Specifically, the mRNAs identified by ReMIx 4 indicated the MAPK signaling cascade to be significant in TNBC. The mRNAs obtained from 5
ReMIx represented about 4% of gene members in the MAPK pathway. Based on TNBC specific 6 results reported by ReMIx, we expanded the MAPK endogenous RNA network by including the 7 mRNAs with TNBC specific-MRE sites, the corresponding microRNAs that have the potential to 8 bind to these sites, and other protein-coding RNAs in the network that have the potential to 9 interact with each other and regulate expression of primary oncogenes and tumor suppressors 1 0 in the MAPK signaling pathway. Based on the results from this study, we provide a list of 1 1 potential mRNA-microRNA candidates that interact with each other at the network level of 1 2 MAPK signaling cascade and could be possible therapeutic targets for TN tumors. 1 3
One of the limitations of this study is that while ReMIx enables identification of candidate 1 4 mRNA and microRNA players via MRE analysis using RNA-Seq data, this does not establish 1 5 the fact that the identified microRNAs are indeed present and expressed in the particular 1 6 disease, in this case, TN tumors. ReMIx results only confirm that the sites on 3'UTR of mRNAs, 1 7
show distinct expression profiles in tumor and thus have the potential to be regulated by 1 8 microRNAs in a disease-specific manner. To complement these results, microRNA expression 1 9 profiles can be used to validate the existence of microRNAs and to check for expression 2 0 correlation with the corresponding mRNA target(s) identified by ReMIx. This study is limited to 2 1 microRNA-mediated interactions; however, several other mechanisms modulate gene 2 2 expression. At the post-transcriptional level, the interplay of other noncoding RNAs, such as 2 3 long non-coding RNAs, circular RNAs, pseudogenes can collectively form the ceRNA network, 2 4 and compete with protein-coding genes for microRNA binding, thereby influencing their ultimate 2 5 impact on gene expression. Also, during transcription, structural and chemical changes such as 1 histone acetylation to determine the accessibility of chromatin domains, and DNA methylation to 2 silence genes, are well-established modes of regulation, especially in cancer. 3
Lately, there has been much focus in research to explore and identify therapeutic 4 strategies to better treat TNBC patients and improve their chances of survival. It has been 5 shown that activation of the MAPK pathway results in cancer cell proliferation and survival in the 6 tumor (Saini K 2010). Previous studies have shown this pathway to be highly prevalent in TN 7 breast cancer as opposed to other breast cancer subtypes (Hoeflich et al. 2009; Balko et al. In conclusion, we demonstrate a novel method of using MREs in the identification of functionally 1 6 relevant mRNA-microRNA interactions that can be potential targets in TNBC. Further, the 1 7 experimental validation of these interactions is warranted in developing these novel therapeutic 1 8 targets. 1 9 2 0 METHODS 1 ReMIx -a novel methodology to compute MRE frequency from RNA-Seq data 2
We developed an innovative bioinformatics approach called ReMIx, which was used to 3 quantify MRE sites at the 3'UTR regions of mRNAs from RNA-Seq data. ReMIx uses reads 4 aligned to the 3'UTR of genes and scans them for evidence of any given MRE sequence. MRE 5 sequences, which are complementary to the seed sequences of microRNAs, are searched in 6 the 3'UTR of genes that are known to be associated with microRNAs (TargetScan -human 7 version 7.0 (Agarwal et al. 2015)). A hypothetical example of this approach is illustrated in 8 Seed sequences for all the conserved microRNA families (n=329) were downloaded 1 6 from TargetScanHuman 7.1, and the corresponding complementary MRE sequences were 1 7 derived using in-house bioinformatics scripts. Figure 6 is a flowchart representation of the 1 8
ReMIx methodology. In ReMIx, the RNA-Seq BAM files for both Tumor and Normal-Adjacent 1 9 were subset to the 3'UTR regions for all genes using the SAMTools suite (Li et al. 2009 ). The 2 0 newly obtained BAM files were converted into a FASTQ format for every gene, using the 2 1 bam2fastx module from Tophat (Trapnell et al. 2009 ). Next, using MRE sequences of individual 2 2 microRNAs and the FASTQ files for corresponding genes, the frequency of each MRE was 2 3 quantified using FIMO (Grant et al. 2011) . MRE sites with p-value < 0.05 were selected from the 2 4 FIMO output for downstream processing. The raw MRE counts were then normalized to account 1 for sample library size, 3'UTR length and 3'UTR GC content per gene. Finally, for every gene 2 and for every conserved microRNA that targets the gene, the normalized MRE counts were 3 reported in a tab-delimited format for each gene-microRNA pair in the Tumor and Normal-4 Adjacent cases separately. counts from CAP-miRSeq were used to obtain the microRNA expression values in the TNBC 2 0 samples.
1
The differential expression analysis of the RNA-Seq data for the TNBC tumor and 2 2 normal-adjacent pairs were obtained using the bioinformatics R package edgeR (Robinson et al. 2 3 2010). The statistical significance threshold used was FDR < 5% and log2FC |2|. For these 13 2 4 pairs of TNBC cases, differential expression analysis of the microRNA sequencing data was 1 performed using the R bioinformatics package called limma (Ritchie et al. 2015) . The statistical 2 threshold used to identify significantly differential expressed microRNAs was adjusted p-value < 3 0.05. 4
Statistical analyses on MRE sites and activated pathway identification 5
Evaluation of MRE sites that represented distinct and TNBC-specific expression as 6 opposed to ER+ and HER2+ subtypes and normal-adjacent cases were obtained using the R 7 The microRNA set analysis tool called TAM2.0 was used to identify cancer-related 1 4 pathways for the 122 microRNAs. Likewise, enriched canonical pathway analysis for 82 genes 1 5 was performed using KEGG and Reactome functional databases. Open source analysis toolkit 1 6
WebGestalt (Wang et al. 2017) was also used for pathway identification by using the option to 1 7 perform Gene set enrichment analysis (GSEA). Identification of the relevance and 1 8 activation/inhibition status of pathways was evaluated using the R package called Signaling 1 9
Pathway Impact Analysis (SPIA). The Bioconductor R package called Pathview (Luo et al. example shows a Tumor and Normal-Adjacent sample with reads mapped to the 3'UTRs of two 2 1 genes, Gene A and Gene B that consist of 2 and 1 MRE sites respectively, with a common site 2 2 (MRE 1). Reads that align with individual MRE sites (vertical dotted lines) are quantified. For 2 3 every MRE site that belongs to a gene, the counts are then statistically evaluated between 1 Tumor and Normal-Adjacent for evidence of differential frequency (as shown in the table). 2 Figure 6 . Flowchart representation of MRE frequency quantification from RNA-Seq BAM. The 3 RNA-Seq BAM is subset to 3'UTR regions of all genes, converted to FASTQ and then 4 processed through FIMO to obtain raw MRE counts per microRNA for every target gene. The 5 raw MRE counts are normalized to account for library size, 3'UTR length and 3'UTR GC content 6 and individual Tumor and Normal-adjacent quantification reports are generated. 7 
